THX Pharma
ALTHX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 670.5% | -28.6% | 68,819.9% | – |
| Gross Profit | -€0 | -€0 | €0 | -€0 |
| % Margin | -14.6% | -1,565.4% | 20% | -1,465,443.5% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -110.8% | -2,492.9% | -1,428.1% | -1,440,519.1% |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -77.3% | -2,304.2% | -1,582.8% | -1,353,889.4% |
| EPS Diluted | -0.21 | -0.88 | -1.23 | -1.66 |
| % Growth | 76.1% | 28.5% | 25.9% | – |
| Operating Cash Flow | -€0 | -€0 | -€0 | -€0 |
| Capital Expenditures | -€0 | -€0 | -€0 | -€0 |
| Free Cash Flow | -€0 | -€0 | -€0 | -€0 |